Research ProgramsClinical-based ResearchKidney CancerDevelopmental Research Projects
Developmental Projects funded from 2003 – present | PI | Institution | Project Title | Year 1 (2003-04) | Iliopoulos, Othon | MGH | Functional Analysis of the BHD Tumor-Suppressor Protein | Libermann, Towia
Jones, Jon | BIDMC | Genetic Classification of Clear Cell RCC | Michaelson, Dror | MGH | The Role of Bone-Targeted Therapy with Zoledronic Acid in Metastatic RCC | Panka, David
Mier, James | BIDMC | Potential synergy between sorafenib and AKT inhibitors against RCC* | Year 2 (2004-05) | Haber, Dan
Rivera, Miguel | MGH | Identification of Novel Genes in Sporadic Wilms Tumor* # | Artavonis-Tsakonas, Spyros | MGH | A Genetic Model for Target identification in VHL-HIF Signaling | Signoretti, Sabina
Moch, Holger | BWH | Molecular Analysis of RCC Using Single Nucleotide Polymorphisms (SNP) Arrays# | Alper, Seth | BIDMC | Role of Carbonic Anhydrase IX in Proliferation and Metastasis of RCC | Dabora, Sandra | BWH | A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas | Olumi, Aria | BIDMC | Pro-apoptotic TRAIL-directed Therapies for the Treatment of Advanced RCC | Ross, Robert
Weissleder, Ralph
| DFCI
MGH | Comparison of pathologic microvessel density and monocrystalline iron oxide nanoparticle-enhanced MRI in evaluationg tumor vascularity in pts undergoing Nx for RCC | Year 3 (2005-06) | Alsop, David
Rofsky, Neil | BIDMC | ASL MRI Blood Flow for Monitoring Response to Anti-angiogenic Therapy* | Avigan, David
Rosenblatt, Jacalyn | BIDMC | Phenotypic and Functional Characteristics of Human T cells Stimulated ex vivo with DC/tumor Fusion Cells and Expanded with CD3, CD28 Ab* | Libermann, Towia
Zerbini, Luiz | BIDMC | The Tyrosine Kinase Receptor Axl, a Novel Therapeutic Target in RCC# | Seth, Pankaj | BIDMC | Role of Angiopoietin like 4 (ANGPTL4) as a VEGF Independent Pro-angiogenesis Factor | Year 4 (2006-07) | Marasco, Wayne
Wu, Anna | DFCI
UCLA | PET Evaluation of RCC Metastases using High-affinity Human Anti-CAIX Monoclonal Antibody with Optimized Pharmacokinetic Properties | Signoretti, Sabina | BWH | Development of Mouse Orthotopic Xenografts of Human RCC# * | Frank, David | DFCI | STAT-Mediated Modulation of HIF Signaling: Molecular Strategies for the Treatment of RCC# | Lenahan (Zarwan), Corine
Rosenblatt, Jacalyn
Avigan, David | BIDMC | The effect of Anti-angiogenic Drugs on Tumor Mediated Immune Suppression and Response to the DC/RCC Fusion Vaccine* | Iliopoulos, Othon | MGH | A Drosophila Genetic Screen for Target Identification in VHL-HIF Signaling | Goldberg, Nahum
Mier, James | BIDMC | Mechanism of RCC Resistance to VEGFR Blockade with Sorafenib* | Year 5 (2007-08) | Panka, David
Cho, Daniel
Mier, James | BIDMC | Potential Synergy Between Triterpenoids and NADPH Oxidase Inhibitors in the Treatment of RCC | Sukhatme, Vikas | BIDMC | LDH-A Inhibitors for the Treatment of Fumarate Hydratase (FH) Associated Hereditary Leiomyomatosis and RCC (HLRCC) | Zimmer, Michael | MGH | Identification of Novel Proteins that inhibit HIF mRNA Translation | Libermann, Towia
Sukhatme, Vikas | BIDMC | Identification of new drugs for treatment of RCC patients using Gene Signatures and the Connectivity Map Database | Extension Year (2008-09) | Cho, Eunyoung
Choueiri, Toni | HSPH
DFCI | Analgesic Use and the Risk of RCC | Bhatt, Rupal | BIDMC | Role of defects in IFNg signaling in escape from VEGFR inhibition | | | | |
|
|